Stéphane Rocchi

Co-founder Biper Therapeutics at BiPER Therapeutics

No bio yet

Links


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


BiPER Therapeutics

BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer


Employees

1-10

Links